首页> 外文会议>Conference on Visualizing and Quantifying Drug Distribution in Tissue >Monitoring receptor heterodimerization along intracellular trafficking pathways using anti-HER2 therapeutic antibodies
【24h】

Monitoring receptor heterodimerization along intracellular trafficking pathways using anti-HER2 therapeutic antibodies

机译:使用抗HER2治疗性抗体监测沿细胞内运输途径的受体异二聚体

获取原文

摘要

Overexpression of Human EGF Receptor 2 (HER2) in cancer is a marker of aggressive metastatic disease and poor prognosis. Anti-HER2 humanized monoclonal antibody trastuzumab (TZM) has been successfully used in the clinic over the last decades. However, a large fraction of eligible patients display resistance to this therapy. This calls for a deeper investigation of HER2 interaction with other members of HER tyrosine kinase receptors and modulation of their endocytic trafficking upon TZM treatment. Forster resonance energy transfer Fluorescence lifetime microscopy (FLIM- FRET) offers a robust approach to monitor HER2 homo and heterodimerization via the reduction of donor fluorophore lifetime. The objective of this study was to assess the dynamics of HER receptor homo and heterodimerization behavior via FLIM-FRET by using near-infrared (NIR) FRET pair labeled anti-HER2 and anti-EGFR therapeutic antibodies in HER2-overexpressing breast cancer cells. In addition, we tested our new deep learning platform DL4FLIM adapted for automated analysis of all datasets. Herein, we report a first attempt to quantify NIR FRET pair labeled cetuximab (CTM, as a donor) and TZM (as an acceptor) binding to their receptors EGFR and HER2 respectively in AU565 cells. As a control, we also performed and human isotype IgG FLIM -FRET and found it completely non-specific. Our data demonstrate both the occurrence of FRET between NIR-labeled probes CTM and TZM as well as between CTM-CTM bound to their respective receptors. This proof-of -principal study demonstrated feasibility of monitoring HER2 hetero receptor FRET FLIM to better understand mechanism of TZM resistance.
机译:人EGF受体2(HER2)在癌症中的过度表达是侵袭性转移性疾病和预后差的标志物。抗HER2人源化单克隆抗体曲妥珠单抗(TZM)在过去几十年中已成功使用。然而,大部分符合条件的患者呈现对该疗法的抵抗力。这要求更深入地调查HER2与酪氨酸激酶受体的其他成员的相互作用以及它们对TZM治疗的内吞贩的调节。 Forster共振能量转移荧光寿命显微镜(Flim-fret)提供了一种稳健的方法,可以通过减少供体荧光团寿命来监测HER2 HOMO和异二种化。本研究的目的是通过使用近红外(NIR)尺寸对标记的抗HER2和抗EGFR治疗抗体在HER2-过度抑制乳腺癌细胞中来评估她的受体同性恋和异二聚体行为的动力学。此外,我们测试了我们的新深度学习平台DL4FLIM适用于所有数据集的自动分析。在此,我们报告第一次尝试将鼻腔摩托对(CTM,作为受体)和TZM(作为受体)与其受体EGFR和HER2分别定量与其受体EGFR和HER2分别定量的试图定量与其受体EGFR和HER2一起定量。作为一种对照,我们还表现出和人类异型IgG Flim-ret,发现它完全非特异性。我们的数据显示了NIR标记探针CTM和TZM之间的褶皱的发生,以及与其各自受体结合的CTM-CTM之间。这种归因的研究证明了监测HER2杂受体FRET的可行性,以更好地理解TZM抗性机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号